Skip to main content
NCBI home page
Springer logoLink to Springer
. 2022 Oct 20;16(1):54–62. doi: 10.1007/s12328-022-01720-7

A case of percutaneous transhepatic stomal varices embolization and partial splenic artery embolization for rectal cancer after CAPOX/BEV chemotherapy: the summary of the stomal varices related to oxaliplatin administration

Shoichiro Mizukami 1, Tatsuya Shonaka 1,✉, Chikayoshi Tani 1, Kazuki Ihara 1, Tomohiro Takeda 1, Mizuho Ohara 1, Kimiharu Hasegawa 1, Mishie Tanino 2, Koji Sawada 3, Yasuo Sumi 1
PMCID: PMC9889487  PMID: 36266604

Abstract

Capecitabine and oxaliplatin (CAPOX) plus bevacizumab (BEV) therapy (CAPOX/BEV) is a standard treatment recommended as the first-line treatment for colorectal cancer recurrence. Recently, sinusoidal obstruction syndrome (SOS) and resulting portal hypertension have been reported as important side effects of oxaliplatin. We herein report a rectal cancer patient who underwent percutaneous transhepatic stoma variceal embolization (PTO) and partial splenic artery embolization (PSE) for stomal variceal bleeding and splenomegaly due to portal hypertension caused by SOS after CAPOX therapy. A 43-year-old man who underwent robot-assisted laparoscopic abdominoperineal resection for advanced lower rectal cancer was started on CAPOX/BEV therapy for early recurrence 1 month after surgery. In the sixth course, splenomegaly rapidly worsened, stomal varices appeared, and the stoma began bleeding. At 5 months after the appearance of stomal varices, the splenomegaly worsened, the frequency of stomal bleeding increased, and PTO was performed. Five months later, PSE was performed for splenomegaly and thrombocytopenia. At 5 months since the PSE, the stoma bleeding has not recurred, and the thrombocytopenia has been corrected. The patient has been able to continue chemotherapy. We suggest that staged treatment by PTO and PSE be considered an important treatment option for stomal varices and splenomegaly associated with SOS.

Keywords: Stomal varices, Sinusoidal obstruction syndrome, Oxaliplatin

Introduction

CAPOX therapy is a standard treatment recommended as adjuvant chemotherapy and primary treatment for recurrence of colorectal cancer, but sinusoidal obstruction syndrome (SOS) has been reported as an important side effect of oxaliplatin [1, 2]. SOS reportedly causes fibrosis and stenosis of sinusoids, which eventually leads to portal hypertension [3, 4], and portal hypertension increases inferior mesenteric vein (IMV) pressure, resulting in the appearance of stoma varicose veins [5].

We herein report a case of rectal cancer in which percutaneous transhepatic stoma variceal embolization (PTO) and partial splenic artery embolization (PSE) were performed due to stomal varices caused by portal hypertension induced by SOS after oxaliplatin administration.

Case report

A 43-year-old man was diagnosed with advanced lower rectal cancer (Rb, cT4b, cN3, cM0, cStage IIIc [6]) (Fig. 1a, b) and underwent robot-assisted laparoscopic abdominoperineal resection with bilateral lymph node dissection. He had no remarkable personal or family history.

Fig. 1.

Fig. 1

Open in a new tab

Colonoscopy and MRI at before the surgical treatment of rectal cancer. a Colonoscopy revealed a half circular 40-mm type 2 tumor in the anterior wall of the lower rectum. b MRI (T2WI: sagittal) revealed an irregular mass on the anterior wall side of the lower rectum; prostate invasion was suspected (arrows)

One month postoperatively, contrast-enhanced computed tomography (CT) revealed multiple enlarged left lateral lymph nodes and para-aortic lymph nodes (Fig. 2a, b), leading to the diagnosis of early recurrence, and CAPOX/BEV therapy (arm: bevacizumab 7.5 mg/kg and oxaliplatin 130 mg/m2 on day 1 and oral capecitabine 2000 mg/m2 on days 1–14, every 3 weeks) was initiated. The splenomegaly worsened rapidly after the sixth course of CAPOX, and the platelet count decreased. He had no abdominal pain suspicious of hepatomegaly and no weight gain.

Fig. 2.

Fig. 2

Open in a new tab

Contrast-enhanced CT findings at the time of early recurrence at the lymph nodes. a The metastatic left lateral lymph node was enlarged (arrowhead). b The para-aortic lymph nodes were enlarged (arrowhead)

Five months after starting chemotherapy, the patient developed stomal varices and began bleeding (approximately 300–500 ml each time). After nine courses of CAPOX/BEV had been administered, the neuropathy worsened, and oxaliplatin was discontinued (total dose of oxaliplatin: 1084 mg/m2). Thereafter, contrast-enhanced CT determined he had progressive disease (PD) [7], and two courses of FOLFIRI plus Aflibercept therapy were administered.

Thirteen months after starting chemotherapy, contrast-enhanced CT revealed worsening of the splenomegaly and stomal varices as well as frequent bleeding from the stoma, so the patient was admitted to the hospital for a close examination and treatment. Hematological and biochemical examinations on admission revealed a slightly low level of hemoglobin 11.0 g/dl and a platelet count of 15.2 × 104/mm3. The coagulation function and hepatobiliary enzyme levels were normal. The liver function was acceptable (Table 1).

Table 1.

Laboratory data on admission

Blood count Biochemistry Infection
 WBC 5840/mm3  Alb 3.8 g/dL  HBs Ag  < 0.01 IU/mL
 Hgb 11.0 g/dl  T.Bil 0.6 mg/dL  HBs Ab  < 2.5 mIU/mL
 Plt 15.2 × 104/mm3  D.Bil 0.1 mg/dL  HCV Ab 0.05 S/CO
Coagulation  AST 25 U/L Tumor marker
 ALT 18 U/L
 PT% 111%  LDH 168 U/L   CEA 13.5 ng/ml
 PT INR 0.92  ALP 211 U/L  CA19-9 72 U/ml
 APTT 27.5 s  γGT 36 U/L Liver function
 Fib 297 μg/mL  BUN 14.8 mg/dL
 FDP 3.6 μg/mL  Cre 0.8 mg/dL  Child Pugh score 5 (A)
 D.D 1.9 μg/mL  CRP  < 0.1 mg/dL  ALBI score − 2.56
 AT-III 116%  NH3 82 µg/dL  MELD score 1
Open in a new tab

Contrast-enhanced CT findings on admission showed a 17 × 7 cm splenomegaly (Fig. 3a) and stomal varices (Fig. 3b–d). A comparison of the CT findings at the time of early recurrence with the CT findings obtained before admission showed that the spleen index (splenic length diameter × splenic width diameter) had doubled, and the stomal varices were highly developed (Fig. 4). The thickness of the liver at the midline of the clavicle was 16 cm, suggesting mild hepatomegaly. No liver metastasis findings were observed during the disease course, and no varicose veins were observed by gastrointestinal endoscopy through the stoma.

Fig. 3.

Fig. 3

Open in a new tab

Contrast-enhanced CT findings at admission. a Severe splenomegaly 17 × 7 cm (dotted arrow). No liver metastases were found. b–d Varicose veins around the stoma (arrow) perfused into the IMV (b axial, c sagittal, d 3D angiography)

Fig. 4.

Fig. 4

Open in a new tab

Clinical course and changes in the platelet count and spleen index

We decided to perform a liver biopsy and percutaneous transhepatic stomal variceal embolization to investigate SOS and treat the stomal varices. We approached the stomal varices from the right branch of portal vein and performed inferior mesenteric vein (IMV) angiography. The peristomal varices were visualized from the inferior abdominal wall vein to the external iliac vein (Fig. 5a). We injected 5% Ethanolamine oleate into the peripheral stomal varices and embolized the central side with Fibered IDC coil® 5 mm × 12 cm and C-Stopper coil®0.016 180 mm × 3.

Fig. 5.

Fig. 5

Open in a new tab

Percutaneous transhepatic obliteration. a Fluoroscopic angiography revealed that the peristomal varices were visualized from the inferior abdominal wall vein to the external iliac vein. b, c Postoperative contrast-enhanced CT revealed the disappearance of stomal varices (arrow) (b axial, c 3D angiography)

Postoperative contrast-enhanced CT revealed the disappearance of the stomal varices (Fig. 5b, c). A histopathological examination of a liver biopsy specimen demonstrated focal central vein narrowing and sinusoidal occlusion by fibrosis, consistent with sinusoidal obstruction syndrome (Fig. 6). Based on the European Society for Blood and Marrow Transplantation (EBMT) criteria, which are currently used to diagnose and classify the severity of SOS, the severity was determined to be mild [8].

Fig. 6.

Fig. 6

Open in a new tab

Histopathological examination findings of a liver biopsy specimen. A trichrome stain demonstrated focal central vein narrowing and sinusoidal occlusion by fibrosis (arrowhead), consistent with sinusoidal obstruction syndrome

We performed PSE 5 months after PTO because the splenomegaly induced thrombocytopenia made it difficult to continue chemotherapy. We punctured the right femoral artery and selectively embolized the middle and inferior pole branches of the splenic artery with Spongel®. Postoperative contrast-enhanced CT showed that the middle to lower poles of the spleen were almost entirely contrast-enhanced, except for some areas, and the embolization effect was about 80% (Fig. 7a, b). The platelet count improved quickly after PSE (Fig. 4). Four months have passed after PSE, and chemotherapy is ongoing without any recurrence of stoma bleeding.

Fig. 7.

Fig. 7

Open in a new tab

Contrast-enhanced CT during PSE. The middle to lower poles of the spleen were poorly contrasted (a. preoperative CT scan, b. postoperative CT scan; arrowhead: boundary of the infarcted spleen)

Discussion

SOS is a systemic endothelial disease that typically presents in the days or weeks after hematopoietic cell transplantation (HCT) with refractory thrombocytopenia, hepatomegaly, ascites, and jaundice, and it can rapidly progress to multiorgan dysfunction and death. SOS develops in up to 15% of adults after HCT [9], but has also been reported as a major side effect of oxaliplatin [1, 2]. It is induced by damage to sinusoidal endothelial cells and amplified by the local inflammatory response and activation of the coagulation-fibrinolysis pathway, leading to severe hepatic necrosis [3, 4]. Regarding the underlying mechanism, oxaliplatin causes the generation of reactive oxygen species, which depletes glutathione in sinusoidal epithelial cells and increases oxidative stress [10]. In addition, oxaliplatin causes depolymerization of actin in sinusoidal epithelial cells and the upregulation of matrix metalloproteinases-2,9 which leads to fibroblast proliferation and endothelial cell loss as well as fibrosis of sinusoids and central veins, resulting in portal hypertension [1, 10–13].

The incidence of SOS after oxaliplatin administration was 48.8–59.0% [14–16], and SOS was reported to be found in 51% of cases of hepatic resection after neoadjuvant chemotherapy and 79% of liver biopsy specimens [1, 11], so there is concern about the high incidence of SOS. Previously, mortality from severe SOS has been reported to exceed 80% [9, 17–19]. In a systematic review of patients with severe SOS after hepatectomy, an increased frequency of postoperative complication rates, complications specific to liver surgery and postoperative liver failure were reported [20]. As for the relationship between the dose of oxaliplatin and the development of SOS, it has been reported that more careful follow-up is important in patients who have received more than 6 courses of oxaliplatin-based chemotherapy [21, 22]. It has been reported that splenomegaly is induced when the total oxaliplatin dose exceeds 1040 mg/mm2 and that 12 courses of FOLFOX therapy and more than 8 courses of CAPOX therapy are risk factors for the development of SOS [23]. Welsh et al. reported that postoperative complications, the reoperation rate, and the duration of hospital stay were increased in cases of hepatic resection performed after oxaliplatin administration when chemotherapy was administered for more than 12 weeks or when the time between chemotherapy discontinuation and resection was less than 4 weeks [24]. In the present case, splenomegaly worsened after the sixth course of CAPOX (oxaliplatin dose: 684 mg/m2), and stoma bleeding occurred in the eighth course. The platelet count decreased with the worsening of splenomegaly, and a liver biopsy at the time of stoma variceal embolization showed scattered fibrosis between hepatocytes and partial strong fibrosis in the central vein, which led to the diagnosis of SOS and portal hypertension.

Stomal varices occur at the border between the intestine and abdominal wall at the stoma-mucosal junction as a blood channel of the portal-systemic shunt under conditions of portal hypertension [5]. A total of 27–31% of patients with portal hypertension due to chronic liver disease reportedly develop varicose veins when colostomy is performed [25].

Since they form on or near the body surface, the site of bleeding is often easy to identify, and the bleeding-related mortality rate is as low as 3–4% [26]. However, bleeding stomal varices present with frequent bleeding and are often difficult to treat [27, 28]. In patients with metastatic multiple liver tumors and ascites, treatment options are limited. Bleeding due to varices is a complication that not only decreases the patient’s quality of life but also leads to progressive anemia, a worsened nutritional status, and a decreased performance status, making interruption of chemotherapy a prognostic factor. Management of stomal varices bleeding and thrombocytopenia due to splenomegaly has a significant impact on the quality of life and continuation of chemotherapy.

The two major elements of treatment are bleeding control of stoma varices and modification of the macrocirculation to improve portal hypertension. Local therapies for hemostasis of stoma varicose veins include compression, suturing, and sclerotherapy, but all are symptomatic, and rebleeding is inevitable. Drug therapies, such as β-blockers, octreotide, and ursodeoxycholic acid, are sometimes used prophylactically, but the efficacy of monotherapy is very limited [29, 30]. Stoma reconstruction is reported to be highly invasive and rebleeding occurs in 75% of cases [31]. Therefore, therapeutic intervention for the feeding vein is necessary. In our case, we chose the PTO approach from the feeding vein.

PTO is a feasible and safe option for stomal variceal bleeding, despite the invasiveness of transhepatic puncture [32–34]. Ishikawa et al. performed PTO in 37 patients with refractory hepatic encephalopathy and gastroesophageal varices and reported that the procedure was successful in all patients, with a recurrence rate of 2.7% [35]. Maciel et al. also reported that stoma variceal embolization with PTO was performed, and the bleeding subsided after 6 months of follow-up [36]. Compared with the method of percutaneous puncture and contrast of varicose veins, the overall image, including varicose veins and collateral vessels, can be grasped, which enables more efficient hemostasis by embolization [36, 37]. In the present case, we performed PTO for bleeding control. Although minimally invasive, PTO provides valuable information based on the findings of a blood flow evaluation and liver biopsy and the response rate is reported to be high. We, therefore, believe that PTO can be an important local treatment option.

After embolization of the stomal varices in our patient, the thrombocytopenia caused by splenomegaly worsened and chemotherapy could not be continued. We, therefore, also needed to address the portal hypertension. Splenectomy [38, 39], PSE [40], transjugular intrahepatic portosystemic shunt (TIPS) [3], and surgical shunt angioplasty have been reported as treatments to reduce portal pressure. PSE is useful as a method to correct abnormal splenic hyperactivity and reduce portal pressure while preserving the important splenic functions [40, 41]. A percutaneous approach through the femoral artery is feasible, and the procedure is short and minimally invasive, taking only one to two hours. It is effective in improving the liver function, decreasing variceal bleeding, treating hepatic encephalopathy, and improving blood cell counts in patients with portal hypertension [42]. A study of the acute effects of PSE on portal and visceral hemodynamics in cirrhotic patients reported that it produced an immediate portal decompression effect without decreasing portal perfusion and increased the blood flow in the hepatic artery and superior mesenteric vein, which was associated with an improved liver function [43]. Splenic abscess is an extremely serious complication, which may be triggered by post-embolization anaerobic bacterial growth, percutaneous contamination by exogenous bacteria, and retrograde infection of intestinal bacteria via portal reflux [44]. Unlike splenectomy, it is possible to selectively determine the extent of embolization. For cases of macro-splenomegaly or a poor hepatic function, it is also important to embolize in fractions from the beginning (keeping the embolization area at 30% per embolization) [40]. Since PSE has a poor immediate effect on stoma variceal bleeding, it needs to be combined with local hemostatic management [39]. After PSE in the present patient, the platelet count improved, and chemotherapy was able to be restarted. It is important to have a high index of suspicion for the diagnosis of hepatic SOS and to initiate treatment promptly. Patients with mild or moderate severity SOS generally do well with supportive care measures alone, but they must be monitored for progression to severe disease [8]. Defibrotide is a sodium salt of single-stranded oligodeoxyribonucleotides derived from DNA of the porcine intestinal mucosa [45] that was approved for the treatment of severe hepatic SOS after HCT in Japan in 2019. The mechanism of action is not well understood, but it may involve endothelial protection, restoration of the thrombo-fibrinolytic balance, and/or anti-inflammatory properties [46, 47]. Defibrotide treatment for severe SOS was associated with improved survival, according to a multicenter study of defibrotide treatment versus matched historical control patients [48], and a systematic review of 17 studies [49]. In Japan, defibrotide is currently approved only for use in severe SOS after HCT; however, the collection of further data on its use will be important because of concerns about the high incidence of SOS caused by oxaliplatin. Currently, we believe that it is better to follow patients with hepatosplenomegaly and collateral hyperplasia with attention to the risk of developing SOS under the use of oxaliplatin and to individualize the treatment as appropriate.

We searched for reports from PubMed (1950 to January 2022) using the keywords “stomal varices”, “stomal variceal”, or “stoma varix”. Among them, we extracted reports of stomal varices related to oxaliplatin-based chemotherapy in colorectal cancer cases and found six reports, including our case [5, 35, 44, 50, 51] (Table 2). There were five cases of liver metastasis, and five cases were diagnosed as SOS. All patients received oxaliplatin-based first-line chemotherapy, five patients received FOLFOX, and only our patient received CAPOX. The median cycle was 11.5 (5–13) courses. Two patients underwent variceal embolization and sclerotherapy via the percutaneous transhepatic approach. One case was treated with palliative ligation and percutaneous sclerotherapy, but rebleeding occurred, and PTO was performed later. None of them had rebleeding of stomal varices after PTO. Our patient underwent PSE, and one patient underwent TIPS for portal hypertension. The patient who underwent TIPS showed worsening of hepatic encephalopathy 6 weeks after the procedure. In our case, after direct embolization of stomal varices with PTO, PSE was safely performed to correct portal hypotension and thrombocytopenia. Five months have passed since PSE, and chemotherapy is ongoing without any recurrence of stoma bleeding.

Table 2.

Reported cases of stomal varices after oxaliplatin-based chemotherapy

No. Author (year) Age Sex Location of CRC Surgical treatment Liver metastasis SOS Other liver condition Chemotherapy Cycle L-OHP (mg/m2) Onset of stomal varices Treatment Recurrent (time to recurrence) Recurrent treatment Treatment for portal hypertension Outcome period (months) Outcome Cause of death
1 E Theophilidou (2012) [44] 64 M R Hartmann’s operation  +   +  FOLFOX 12 85 NA Ligation/PS  +  (1 month) PTO None 6 Alive
2 Sonoda H (2015) [5] 65 F R Sigmoid colostomy  +   +  mFOLFOX6 12 85 Unknown TIPS – – None 12 Death Cancer death
3 MJ Maciel (2016) [35] 68 F R Palliative colostomy  +  NA mFOLFOX6 5 85 4 cycles from start of chemotherapy PTO – – None 6 Alive
4 Yamaguchi H (2018) [50] 27 F T Hartmann’s operation  +   +  Stenosis of RHV/IVC mFOLFOX6 + Bev 13 85 6 mos. from start of chemotherapy PE/PS – – None NA Death Liver failure
5 Uehara H (2020) [51] 66 F R Colostomy + ileum bypass → LAR  → liver resection  +   +  mFOLFOX6 + Bev 9 85 4 years from end of chemotherapy Open abdominal sclerotherapy – – None 12 Alive
6 Our case 46 M R APR –  +  CAPOX + Bev 11 125 5 mos. from start of chemotherapy PTO – – PSE 7 Alive
Open in a new tab

M male, F female, CRC colorectal cancer, R rectum, T transverse, SOS sinusoidal obstruction syndrome, L-OHP oxaliplatin, APR abdominoperineal resection, LAR low anterior resection, NA not available, RHV right hepatic vein, IVC inferior vena cava, mos. months, PS percutaneous sclerotherapy, PSE partial splenic embolization, PTO percutaneous transhepatic obliteration, TIPS transjugular intrahepatic portosystemic shunt, PE percutaneous embolization used

Conclusion

We encountered a case of stomal varices due to portal hypertension caused by SOS after oxaliplatin administration that was treated by PTO and PSE. Considering the invasiveness and complications, PTO and PSE were the optimal choices. We suggest that staged treatment be considered an important treatment option for stomal varices and splenomegaly associated with SOS.

Acknowledgements

We thank Japan Medical Communication for English language editing.

Declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15:460–466. doi: 10.1093/annonc/mdh095. [DOI] [PubMed] [Google Scholar]
  • 2.Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24:2065–2072. doi: 10.1200/JCO.2005.05.3074. [DOI] [PubMed] [Google Scholar]
  • 3.Mohty M, Malard F, Abecassis M, et al. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT) Bone Marrow Transplant. 2015;50:781. doi: 10.1038/bmt.2015.52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Carreras E, Diaz-Ricart M. The role of the endothelium in the short-term complications of hematopoietic SCT. Bone Marrow Transplant. 2011;46:1495. doi: 10.1038/bmt.2011.65. [DOI] [PubMed] [Google Scholar]
  • 5.Sonoda H, Morishita H, Shioaki Y. TIPS is effective for bleeding of stomal varices: report of a case. JJCS. 2015;40:144–147. [Google Scholar]
  • 6.Japanese Society for Cancer of the Colon and Rectum Japanese classification of colorectal, appendiceal, and Anal carcinoma: the 3d english edition [secondary publication] J Anus Rectum Colon. 2019;3:175–195. doi: 10.23922/jarc.2019-018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1) Eur J Cancer. 2009;45:228–247. doi: 10.1016/j.ejca.2008.10.026. [DOI] [PubMed] [Google Scholar]
  • 8.Mohty M, Malard F, Abecassis M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016;51:906–912. doi: 10.1038/bmt.2016.130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Coppell JA, Richardson PG, Soiffer R, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010;16:157–168. doi: 10.1016/j.bbmt.2009.08.024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. 2007;110:2761–2767. doi: 10.1002/cncr.23099. [DOI] [PubMed] [Google Scholar]
  • 11.Hubert C, Sempoux C, Horsmans Y, et al. Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases? Liver Int. 2007;27:938–943. doi: 10.1111/j.1478-3231.2007.01511.x. [DOI] [PubMed] [Google Scholar]
  • 12.Grávalos C, García-Escobar I, García-Alfonso P, et al. Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II–III colorectal cancer. Oncology. 2009;76:363–368. doi: 10.1159/000210025. [DOI] [PubMed] [Google Scholar]
  • 13.Deleve LD, Wang X, Tsai J, et al. Sinusoidal obstruction syndrome (veno-occlusive disease) in the rat is prevented by matrix metalloproteinase inhibition. Gastroenterology. 2003;123:882–890. doi: 10.1016/s0016-5085(03)01056-4. [DOI] [PubMed] [Google Scholar]
  • 14.Colli A, Pozzoni P, Berzuini A, et al. Decompensated chronic heart failure: increased liver stiffness measured by means of transient elastography. Radiology. 2010;257:872–878. doi: 10.1148/radiol.10100013. [DOI] [PubMed] [Google Scholar]
  • 15.Mukund A, Pargewar SS, Desai SN, et al. Changes in liver congestion in patients with Budd-Chiari syndrome following endovascular interventions: assessment with transient elastography. J Vasc Interv Radiol. 2017;28:683–687. doi: 10.1016/j.jvir.2016.11.091. [DOI] [PubMed] [Google Scholar]
  • 16.Jalal Z, Iriart X, De Lédinghen V, et al. Liver stiffness measurements for evaluation of central venous pressure in congenital heart diseases. Heart. 2015;101:1499–1504. doi: 10.1136/heartjnl-2014-307385. [DOI] [PubMed] [Google Scholar]
  • 17.Sakai M, Strasser SI, Shulman HM, et al. Severe hepatocellular injury after hematopoietic cell transplant: incidence, etiology and outcome. Bone Marrow Transplant. 2009;44:441. doi: 10.1038/bmt.2009.56. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Carreras E. How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation. Br J Haematol. 2015;168:481. doi: 10.1111/bjh.13215. [DOI] [PubMed] [Google Scholar]
  • 19.Zhao J, van Mierlo KMC, Gómez-Ramírez J, et al. Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases. Br J Surg. 2017;104:990. doi: 10.1002/bjs.10572. [DOI] [PubMed] [Google Scholar]
  • 20.Nakano H, Oussoultzoglou E, Rosso E, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008;247:118–124. doi: 10.1097/SLA.0b013e31815774de. [DOI] [PubMed] [Google Scholar]
  • 21.Karoui M, Penna C, Amin-Hashem M, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243:1–7. doi: 10.1097/01.sla.0000193603.26265.c3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Poston GJ. The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer. Eur J Surg Oncol. 2005;31:325–330. doi: 10.1016/j.ejso.2005.01.008. [DOI] [PubMed] [Google Scholar]
  • 23.Yamaguchi K, Ryu Y, Saisho K, et al. Splenomegaly and esophageal varices associated with XELOX plus bevacizumab therapy for non-resectable advanced colon cancer : a case report. Jpn J Cancer Clin. 2014;60:447–452. [Google Scholar]
  • 24.Welsh FK, Tilney HS, Tekkis PP, et al. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer. 2007;96:1037. doi: 10.1038/sj.bjc.6603670. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Fucini C, Wolff BG, Dozois RR, et al. Bleeding from peristomal varices: perspective on prevention and treatment. Dis Colon Rectum. 1991;34:1073–1078. doi: 10.1007/BF02050064. [DOI] [PubMed] [Google Scholar]
  • 26.Bret JS, Abdullah AF, Michael R, et al. Bleeding stromal varices: case series and systematic review of the literature. Clin Gastroenterol Hepatol. 2008;6:346–352. doi: 10.1016/j.cgh.2007.12.047. [DOI] [PubMed] [Google Scholar]
  • 27.Kubokawa M, Akahoshi K, Kasiwabara Y, et al. Clinical characteristics of ectopic varices. JJPH. 2009;15:169–175. [Google Scholar]
  • 28.Matsui S, Kudo M. The clinical characteristics, diagnosis and treatment for patients presenting with duodenal varices. JJPH. 2009;15:190–194. [PubMed] [Google Scholar]
  • 29.Vidal V, Joly L, Perreault P, et al. Usefulness of transjugular intrahepatic portosystemic shunt in the management of bleeding ectopic varices in cirrhotic patients. Cardiovasc Intervent Radiol. 2006;29:216–219. doi: 10.1007/s00270-004-0346-4. [DOI] [PubMed] [Google Scholar]
  • 30.Conte JV, Arcomano TA, Naficy MA, et al. Treatment of bleeding varices. Report of a case and review of the literature. Dis Colon Rectum. 1990;33:308–314. doi: 10.1007/BF02055474. [DOI] [PubMed] [Google Scholar]
  • 31.Terai S, Terada I, Shinbo T, et al. A case of bleeding stomal varices treated by percutaneous transhepatic variceral obliteration. J Jpn Surg Assoc. 2015;76:79–84. [Google Scholar]
  • 32.Arulraj R, Mangat KS, Tripathi D. Embolization of bleeding stomal varices by direct percutaneous approach. Cardiovasc Intervent Radiol. 2011;34:S210–S213. doi: 10.1007/s00270-010-9886-y. [DOI] [PubMed] [Google Scholar]
  • 33.Kwok AC, Wang F, Maher R, et al. The role of minimally invasive percutaneous embolization technique in the management of bleeding stomal varices. J Gastrointest Surg. 2013;17:1327–1330. doi: 10.1007/s11605-013-2180-y. [DOI] [PubMed] [Google Scholar]
  • 34.Ishikawa T, Imai M, Ko M, et al. Percutaneous transhepatic obliteration and percutaneous transhepatic sclerotherapy for intractable hepatic encephalopathy and gastric varices improves the hepatic function reserve. Biomed Rep. 2017;6:99–102. doi: 10.3892/br.2016.811. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Maciel MJ, Pereira OI, Motta Leal Filho JM, et al. Peristomal variceal bleeding treated by coil embolization using a percutaneous transhepatic approach. WJCC. 2016;4:25–29. doi: 10.12998/wjcc.v4.i1.25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Kishimoto K, Hara A, Arita T, et al. Stomal varices: treatment by percutaneous transhepatic coil embolization. Cardiovasc Intervent Radiol. 1999;22:523–525. doi: 10.1007/s002709900445. [DOI] [PubMed] [Google Scholar]
  • 37.Kobayashi N, Fukuhara T, Mesaki K, et al. A case of bleeding stomal varices during the course of oxaliplatin-based chemotherapy for recurrent rectal cancer. Jpn J Cancer Chemother. 2014;41:905–907. [PubMed] [Google Scholar]
  • 38.Luz JH, Luz PM, Marchiori E, et al. Partial splenic embolization to permit continuation of systemic chemotherapy. Cancer Med. 2016;5:2715–2720. doi: 10.1002/cam4.856. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Kato K, Nakama R, Tanimura K, et al. Treatment of refractory stomal variceal hemorrhage with partial splenic artery embolization: a case report. Interv Radiol. 2019;4:48–52. [Google Scholar]
  • 40.Yoshida H, Mamada H, Taniai N, et al. Partial splenic embolization. JJPH. 2012;18:215–216. [Google Scholar]
  • 41.Koconis KG, Singh H, Soares G. Partial splenic embolization in the treatment of patients with portal hypertension: a review of the english language literature. J Vasc Interv Radiol. 2007;18:463–481. doi: 10.1016/j.jvir.2006.12.734. [DOI] [PubMed] [Google Scholar]
  • 42.Helaly AZ, Al-Warraky MS, El-Azab GI, et al. Portal and splanchnic hemodynamics after partial splenic embolization in cirrhotic patients with hypersplenism. APMIS. 2015;123:1032–1039. doi: 10.1111/apm.12470. [DOI] [PubMed] [Google Scholar]
  • 43.Masada T, Tanaka T, Sakaguchi H, et al. Coils versus gelatin particles with or without intraarterial antibiotics for partial splenic embolization: a comparative evaluation. J Vasc Interv Radiol. 2014;25:852–858. doi: 10.1016/j.jvir.2013.12.563. [DOI] [PubMed] [Google Scholar]
  • 44.Theophilidou E, Waraich N, Raza T, et al. Liver metastases, a rare cause of portal hypertension and stoma bleeding. Brief review of literature. Int J Surg Case Rep. 2012;3:173–176. doi: 10.1016/j.ijscr.2011.11.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Kornblum N, Ayyanar K, Benimetskaya L, et al. Defibrotide, a polydisperse mixture of single-stranded phosphodiester oligonucleotides with lifesaving activity in severe hepatic veno-occlusive disease: clinical outcomes and potential mechanisms of action. Oligonucleotides. 2006;16:105. doi: 10.1089/oli.2006.16.105. [DOI] [PubMed] [Google Scholar]
  • 46.Richardson PG, Corbacioglu S, Ho VT, et al. Drug safety evaluation of defibrotide. Expert Opin Drug Saf. 2013;12:123. doi: 10.1517/14740338.2012.749855. [DOI] [PubMed] [Google Scholar]
  • 47.Pescador R, Capuzzi L, Mantovani M, et al. Defibrotide: properties and clinical use of an old/new drug. Vascul Pharmacol. 2013;59:1. doi: 10.1016/j.vph.2013.05.001. [DOI] [PubMed] [Google Scholar]
  • 48.Richardson PG, Riches ML, Kernan NA, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016;127:1656. doi: 10.1182/blood-2015-10-676924. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Richardson P, Aggarwal S, Topaloglu O, et al. Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) Bone Marrow Transplant. 2019;54:1951. doi: 10.1038/s41409-019-0474-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Yamaguchi H, Furuichi Y, Kasai Y, et al. A case of severe stenosis of hepatic veins and inferior vena cava with stomal variceal bleeding induced by oxaliplatin-based chemotherapy. Clin J Gastroenterol. 2018;11:150–155. doi: 10.1007/s12328-017-0814-4. [DOI] [PubMed] [Google Scholar]
  • 51.Uehara H, Kawanaka H, Nakanoko T, et al. Successful hybrid surgery for ileal conduit stomal varices following oxaliplatin-based chemotherapy in a patient with advanced colorectal cancer. Surg Case Rep. 2020;6:236. doi: 10.1186/s40792-020-01021-6. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical Journal of Gastroenterology are provided here courtesy of Springer

RESOURCES